

THIRD ANNUAL

GI ReConnect



June 1-3, 2023

**Hyatt Regency Huntington Beach Resort
Huntington Beach, California**

Provided by:





Positioning Therapies Bioexposed Crohn's Disease

Parambir S. Dulai, MD
Northwestern University

Disclosure Statement

All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, the University of Cincinnati staff and the Gi Health Foundation staff have no relationships to disclose.


Disclosures

- Consulting: Abbvie, Abivax, Adiso, BMS, GSK, Janssen, Lilly, Pfizer, Roivant, Takeda

Comparative Efficacy of Agents in Anti-TNF Exposed Patients: Network Meta-Analysis of Clinical Remission

Medications	Relative Effect (Odds Ratio, 95% CI)	Overall Quality of Evidence
Selected Agents vs Placebo		
Adalimumab	3.57 (1.66-7.65)	Moderate (imprecision, indirectness)
Vedolizumab	1.53 (0.77-3.06)	Low (very serious imprecision)
Ustekinumab	2.58 (1.50-4.44)	Moderate (imprecision)
Selected Agents vs Adalimumab		
Vedolizumab	0.43 (0.15-1.20)	Very low (very serious imprecision, intransitivity)
Ustekinumab	0.72 (0.28-1.85)	Very low (very serious imprecision, intransitivity)
Selected Agents vs Vedolizumab		
Ustekinumab	1.68 (0.68-4.15)	Very low (very serious imprecision, intransitivity)


Ustekinumab after Biologic Exposure



- Multicenter retrospective study of over 1,000 CD patients (SUCCESS Consortium)
- **Lower effectiveness for Ustekinumab with increasing biologic exposures**

Vedolizumab (VDZ) VERSIFY: Endoscopic response and remission with VDZ lower in anti-TNF exposed patients with CD

- Endoscopic response rates were greater than endoscopic remission rates
- Both followed a similar pattern, with lower rates in anti-TNF exposed patients



Endoscopic response: SES-CD $\geq 50\%$ reduction from baseline.


Endoscopic remission: SES-CD ≤ 4 .

CD, Crohn's disease; SES-CD, Simple Endoscopic Score for CD; TNF α , tumor necrosis factor alpha; VDZ, vedolizumab.


EVOLVE study: 1st Line Anti-TNF versus 2nd Line Anti-TNF after VDZ

Not all Biologic Exposures are Created Equally

- Multicenter retrospective study of 579 CD and UC patients (results similar in both diseases)
- **Results suggest that first-line VDZ does not have an impact on the effectiveness of subsequent anti-TNF therapy in real-world clinical practice**




Risankizumab and Biologic Exposures




Risankizumab and 1 Biologic Exposure

ADVANCE - Week 12 Endoscopic Response




MOTIVATE - Week 12 Endoscopic Response




Upadacitinib and 1 Biologic Exposure

U-EXCEED/EXCEL – Week 12 Endoscopic Response




U-ENDURE – Week 52 Endoscopic Response




Updated Network Meta-Analysis

Failure to Induce Clinical Remission



Relapse of Disease Activity During Maintenance



- Risankizumab ranked first for induction of clinical remission in biologic exposed
- Upadacitinib 30mg ranked first for maintenance of clinical remission in biologic exposed

Conclusion

- Prior antiTNF exposure associated with reduced efficacy for vedolizumab and ustekinumab
- Exposure to other biologics may not impact efficacy of antiTNF efficacy (more data needed)
- Risankizumab and Upadacitinib with good efficacy after all biologic exposures